New shot aims to silence hepatitis b for good
NCT ID NCT07246889
First seen Jan 06, 2026 · Last updated May 21, 2026 · Updated 20 times
Summary
This study tests an experimental drug called AHB-137 in about 577 adults with a type of chronic hepatitis B (HBeAg-negative) who are already on standard antiviral pills. The goal is to see if adding AHB-137 injections can clear the hepatitis B surface antigen (HBsAg) from the blood and keep the virus undetectable after stopping all hepatitis B medications. Participants receive either AHB-137 or a placebo, and researchers monitor safety and how long the virus stays suppressed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AusperBio Investigational Site
Hefei, Anhui, China
-
AusperBio Investigational Site
Beijing, Beijing Municipality, China
-
AusperBio Investigational Site
Chongqing, Chongqing Municipality, China
-
AusperBio Investigational Site
Fuzhou, Fujian, China
-
AusperBio Investigational Site
Xiamen, Fujian, China
-
AusperBio Investigational Site
Lanzhou, Gansu, China
-
AusperBio Investigational Site
Foshan, Guangdong, China
-
AusperBio Investigational Site
Guangzhou, Guangdong, China
-
AusperBio Investigational Site
Shenzhen, Guangdong, China
-
AusperBio Investigational Site
Liuzhou, Guangxi, China
-
AusperBio Investigational Site
Nanning, Guangxi, China
-
AusperBio Investigational Site
Guiyang, Guizhou, China
-
AusperBio Investigational Site
Zunyi, Guizhou, China
-
AusperBio Investigational Site
Haikou, Hainan, China
-
AusperBio Investigational Site
Zhengzhou, Henan, China
-
AusperBio Investigational Site
Wuhan, Hubei, China
-
AusperBio Investigational Site
Changsha, Hunan, China
-
AusperBio Investigational Site
Nanjing, Jiangsu, China
-
AusperBio Investigational Site
Zhenjiang, Jiangsu, China
-
AusperBio Investigational Site
Nanchang, Jiangxi, China
-
AusperBio Investigational Site
Changchun, Jilin, China
-
AusperBio Investigational Site
Shenyang, Liaoning, China
-
AusperBio Investigational Site
Shanghai, Shanghai Municipality, China
-
AusperBio Investigational Site
Taiyuan, Shanxi, China
-
AusperBio Investigational Site
Xi’an, Shanxi, China
-
AusperBio Investigational Site
Chengdu, Sichuan, China
-
AusperBio Investigational Site
Kunming, Yunnan, China
-
AusperBio Investigational Site
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.